AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12361104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of ipecac syrup
Number of subjects: 12
Study 10603720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballpoint pen test (BPT) for sensory function
Number of subjects: 53
Study 10603720 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Semmes Weinstein monofilament test (SWM) for sensory function
Number of subjects: 53
Study 10603720 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary muscle testing (VMT) for motor function
Number of subjects: 53
Study 7857870 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-acetylenic androstenedione (Plomestane)
Number of subjects: 0
Study 7857870 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-acetylenic deoxycorticosterone
Number of subjects: 0
Study 1941408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal alone (OM)
Number of subjects: 8
Study 1941408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal-sucrose (OMS)
Number of subjects: 8
Study 1941408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal-protein (OMP)
Number of subjects: 8
Study 1941408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal with protein and sucrose (OMPS)
Number of subjects: 8
Study 1941408 — intervention group
Group type: COMPARATOR
Intervention: Oatmeal (OM) and Oatmeal-sucrose (OMS)
Number of subjects: 8
Study 1941408 — intervention group
Group type: COMPARATOR
Intervention: Oatmeal-protein (OMP) and Oatmeal with protein and sucrose (OMPS)
Number of subjects: 8
Study 7123952 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-methyl-digoxin (BMD) 0.5 mg
Number of subjects: 30
Study 7123952 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.75 mg
Number of subjects: 30
Study 7123952 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-methyl-digoxin (BMD)
Number of subjects: 30
Study 7123952 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 30
Study 30983518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious-affirmation through a fictional story
Number of subjects: 832
Study 30983518 — intervention group
Group type: COMPARATOR
Intervention: Traditional self-affirmation (not explicitly detailed in the abstract)
Number of subjects: 832
Study 29695706 — intervention group
Group type: EXPERIMENTAL
Intervention: LEI + MR
Number of subjects: 110
Study 29695706 — intervention group
Group type: COMPARATOR
Intervention: LEI
Number of subjects: 110
Study 27600897 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolatan (latanoprost 0.005%) once daily in the evening
Number of subjects: 35
Study 27600897 — intervention group
Group type: COMPARATOR
Intervention: Xalatan (latanoprost 0.005%) once daily in the evening
Number of subjects: 35
Study 24854807 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cognitive restraint during the weight loss intervention
Number of subjects: 49
Study 24854807 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible restraint increase during the WLM intervention
Number of subjects: 49
Study 24854807 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of rigid restraint during the follow-up period
Number of subjects: 49
Study 22776980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis
Number of subjects: 43
Study 22776980 — intervention group
Group type: EXPERIMENTAL
Intervention: B. lactis with Lactobacillus rhamnosus GG
Number of subjects: 43
Study 22776980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20032239 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform dropped (8 cm, 0.9 g acceleration)
Number of subjects: 19
Study 20032239 — intervention group
Group type: COMPARATOR
Intervention: Platform held at small inclination (up to +/-3 degrees)
Number of subjects: 19
Study 20032239 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform dropped
Number of subjects: 19
Study 20032239 — intervention group
Group type: COMPARATOR
Intervention: Platform held at small inclination
Number of subjects: 19
Study 18534330 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish-style massage therapy
Number of subjects: 44
Study 18534330 — intervention group
Group type: COMPARATOR
Intervention: Light-touch bodywork control
Number of subjects: 44
Study 18534330 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 44
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 327
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 327
Study 16014203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted indirect comparison method
Number of subjects: 327
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive method
Number of subjects: 327
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct evidence from RCTs
Number of subjects: 327
Study 16014203 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect comparisons
Number of subjects: 327
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 18
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 18
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 18
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg
Number of subjects: 18
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose proportionality
Number of subjects: 18
Study 14512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 to 80 mg)
Number of subjects: 18
Study 11028253 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg methylphenidate HCl
Number of subjects: 0
Study 11028253 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg methylphenidate HCl
Number of subjects: 0
Study 11028253 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg methylphenidate HCl
Number of subjects: 0
Study 11028253 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of methylphenidate HCl
Number of subjects: 0
Study 9188114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg.kg‐1
Number of subjects: 132
Study 9188114 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 1 mg.kg‐1
Number of subjects: 132
Study 8195852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim, 400 mg loading dose followed by 200 mg daily for 10 days
Number of subjects: 60
Study 8195852 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline, 200 mg loading dose followed by 100 mg daily for 10 days
Number of subjects: 60
Study 3522770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single initial 1500 mg dose of rifampin plus daily doses of 100 mg of dapsone
Number of subjects: 15
Study 3522770 — intervention group
Group type: COMPARATOR
Intervention: Weekly doses of 900 mg of rifampin plus daily doses of 100 mg of dapsone
Number of subjects: 15
Study 29672747 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress for UIA
Number of subjects: 1492
Study 29672747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic perceived stress at home (previous year) for UIA
Number of subjects: 1492
Study 29672747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic perceived stress at home (previous year) for ASAH
Number of subjects: 1492
Study 29672747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong exposure to stress for UIA
Number of subjects: 1492
Study 29672747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong exposure to stress for ASAH
Number of subjects: 1492
Study 29694504 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O EPAP
Number of subjects: 15
Study 29694504 — intervention group
Group type: COMPARATOR
Intervention: Non-EPAP
Number of subjects: 15
Study 27160957 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Citrulline (6 g/d) for 14 d
Number of subjects: 16
Study 27160957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24527505 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella
Number of subjects: 427
Study 24527505 — intervention group
Group type: COMPARATOR
Intervention: IABP
Number of subjects: 427
Study 22914710 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing
Number of subjects: 100
Study 22914710 — intervention group
Group type: COMPARATOR
Intervention: Conventional coagulation analyses
Number of subjects: 100
Study 20362677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical method for smoothing in cortical thickness analysis
Number of subjects: 0
Study 20362677 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedures for smoothing in cortical thickness analysis
Number of subjects: 0
Study 18047609 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetin 0.03% plus niacinamide 4%
Number of subjects: 52
Study 18047609 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide 4%
Number of subjects: 52
Study 18047609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16040442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic insertion of standardized class I inlays using high viscosity composite resin material (Tetric Ceram)
Number of subjects: 0
Study 16040442 — intervention group
Group type: COMPARATOR
Intervention: Manual insertion of standardized class I inlays using high viscosity composite resin material (Tetric Ceram)
Number of subjects: 0
Study 16040442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic insertion of high and medium viscosity composite resin materials
Number of subjects: 0
Study 16040442 — intervention group
Group type: COMPARATOR
Intervention: Manual insertion of high viscosity composite resin material
Number of subjects: 0
Study 16040442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic insertion of three composite resin materials
Number of subjects: 0
Study 16040442 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of filler distribution
Number of subjects: 0
Study 12171842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg daily oral corticosteroids
Number of subjects: 86
Study 12171842 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg daily oral corticosteroids
Number of subjects: 86
Study 10404930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of psychotropic medication
Number of subjects: 93
Study 10404930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 93
Study 10404930 — intervention group
Group type: COMPARATOR
Intervention: Continuing to take psychotropic medication
Number of subjects: 93
Study 10404930 — intervention group
Group type: COMPARATOR
Intervention: No exercise program
Number of subjects: 93
Study 7750285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) containing low doses of oestrogens and progestogens (Triquilar, Trinovum or Cilest)
Number of subjects: 87
Study 2147600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 6
Study 2147600 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 6
Study 2147600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine + GHRH
Number of subjects: 6
Study 2147600 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1‐29)‐NH2
Number of subjects: 6
Study 7032184 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops
Number of subjects: 10
Study 7032184 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 3.0% eye drops
Number of subjects: 10
Study 7032184 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 31053134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly incremental reductions in oral corticosteroid (OCS) dose
Number of subjects: 135
Study 31053134 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of daily OCS dose by 5 mg/day
Number of subjects: 135
Study 28085986 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated glass fiber posts
Number of subjects: 143
Study 28085986 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made glass fiber posts
Number of subjects: 143
Study 28085986 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cores without posts
Number of subjects: 143
Study 28085986 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy-based wrought posts and cast cores
Number of subjects: 143
Study 25531289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 231
Study 25531289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 231
Study 25531289 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire study population
Number of subjects: 231
Study 25531289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with energy expenditure adjustment
Number of subjects: 231
Study 25531289 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 231
Study 23669821 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBINED training
Number of subjects: 28
Study 23669821 — intervention group
Group type: COMPARATOR
Intervention: PLYO training
Number of subjects: 28
Study 22293680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose caffeine (200 mg total from 2 pieces of chewing gum) administered at 3 different time points (‐35, ‐5, and +15 minutes) during cycling exercise
Number of subjects: 8
Study 22293680 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the other 2 points and at all 3 points in the control trial
Number of subjects: 8
Study 20216490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound irradiation administered to the pressure ulcer through the same dressing used in standard treatment (pulsed ultrasound, 20% duty cycle, 0.5W/cm2, 1MHz or 3MHz, for 10 minutes, five times weekly)
Number of subjects: 5
Study 20216490 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 5
Study 17545341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package comprising intense education, a range of reporting options, changes in report management and enhanced feedback
Number of subjects: 0
Study 17545341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 0
Study 15767639 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg daily
Number of subjects: 255
Study 15767639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 12077008 — intervention group
Group type: EXPERIMENTAL
Intervention: Asperger's syndrome
Number of subjects: 21
Study 12077008 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study 9822184 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (ultra-short acting beta-blocker)
Number of subjects: 0
Study 9822184 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic arrest
Number of subjects: 0
Study 7840071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose starch
Number of subjects: 24
Study 7840071 — intervention group
Group type: COMPARATOR
Intervention: Standard starch (70% amylopectin, 30% amylose)
Number of subjects: 24
Study 2375292 — intervention group
Group type: EXPERIMENTAL
Intervention: iopanoic acid
Number of subjects: 8
Study 2375292 — intervention group
Group type: COMPARATOR
Intervention: underfeeding alone (UF)
Number of subjects: 8
Study 6958476 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and beta 2-adrenergic agonist terbutaline (Group 2)
Number of subjects: 14
Study 6958476 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (Group 1)
Number of subjects: 14
Study 6958476 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-adrenergic agonist alone (additional group of 7 patients)
Number of subjects: 14
Study 31775297 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 151
Study 28498374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 30
Study 28498374 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival saline (control)
Number of subjects: 30
Study 26489050 — intervention group
Group type: EXPERIMENTAL
Intervention: Peristaltic external pneumatic compression (EPC) for 30 minutes
Number of subjects: 0
Study 26489050 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 23326171 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGT)
Number of subjects: 71
Study 23326171 — intervention group
Group type: COMPARATOR
Intervention: Transpancreatic precut sphincterotomy (TPS)
Number of subjects: 71
Study 21791902 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls
Number of subjects: 10662
Study 21791902 — intervention group
Group type: COMPARATOR
Intervention: Letters
Number of subjects: 10662
Study 19745642 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 18
Study 19745642 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 18
Study 19745642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20069077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day plus aspirin 81 mg/day
Number of subjects: 181
Study 20069077 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin 81 mg/day
Number of subjects: 181
Study 16099343 — intervention group
Group type: EXPERIMENTAL
Intervention: Children attending day-care centers (DCC)
Number of subjects: 152
Study 16099343 — intervention group
Group type: COMPARATOR
Intervention: Public DCC
Number of subjects: 152
Study 16099343 — intervention group
Group type: COMPARATOR
Intervention: Private DCC
Number of subjects: 152
Study 16099343 — intervention group
Group type: COMPARATOR
Intervention: Demographic features
Number of subjects: 152
Study 12512888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic filling material (CF)
Number of subjects: 20
Study 12512888 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (RC)
Number of subjects: 20
Study 12512888 — intervention group
Group type: COMPARATOR
Intervention: Enamel (E)
Number of subjects: 20
Study 12512888 — intervention group
Group type: EXPERIMENTAL
Intervention: Customary oral hygiene
Number of subjects: 20
Study 12512888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglected oral hygiene
Number of subjects: 20
Study 9161646 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmapine (generic brand of carbamazepine)
Number of subjects: 18
Study 9161646 — intervention group
Group type: EXPERIMENTAL
Intervention: Carzepine (generic brand of carbamazepine)
Number of subjects: 18
Study 9161646 — intervention group
Group type: COMPARATOR
Intervention: Tegretol (proprietary brand of carbamazepine)
Number of subjects: 18
Study 7906572 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched eggs
Number of subjects: 23
Study 7906572 — intervention group
Group type: COMPARATOR
Intervention: Regular eggs
Number of subjects: 23
Study 3300903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 33
Study 3300903 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 33
Study 3300903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11823765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 27849
Study 30346669 — intervention group
Group type: EXPERIMENTAL
Intervention: GHP - 35% hydrogen peroxide gel
Number of subjects: 40
Study 30346669 — intervention group
Group type: COMPARATOR
Intervention: GCP - 37% carbamide peroxide gel
Number of subjects: 40
Study 26700703 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response (T0) after induction chemo-RT
Number of subjects: 119
Study 26700703 — intervention group
Group type: COMPARATOR
Intervention: Near-complete response (Ta or Tis) after induction chemo-RT
Number of subjects: 119
Study 26700703 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response (T0) and near-complete response (Ta or Tis) after induction chemo-RT
Number of subjects: 119
Study 24284437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoleucine (5‐216 mg · kg(‐1) · d(‐1))
Number of subjects: 83
Study 24284437 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (5‐370 mg · kg(‐1) · d(‐1))
Number of subjects: 83
Study 24284437 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine (5‐236 mg · kg(‐1) · d(‐1))
Number of subjects: 83
Study 22929451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drop of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution
Number of subjects: 15
Study 22929451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution
Number of subjects: 15
Study 22929451 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (treatment reference group)
Number of subjects: 15
Study 22929451 — intervention group
Group type: COMPARATOR
Intervention: 0 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (control group)
Number of subjects: 15
Study 21035594 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 212
Study 21035594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 18579668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3000 mg/d
Number of subjects: 513
Study 18579668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3750 mg/d
Number of subjects: 513
Study 18579668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 4500 mg/d
Number of subjects: 513
Study 18579668 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated lanthanum carbonate
Number of subjects: 513
Study 15771694 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy programme for 6 months
Number of subjects: 25
Study 15771694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 12466159 — intervention group
Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 650
Study 12466159 — intervention group
Group type: COMPARATOR
Intervention: Control group (enucleation)
Number of subjects: 650
Study 10622067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 122
Study 8963030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid (R2)
Number of subjects: 6